Identification of an optimized receptor-binding domain-based subunit vaccine against SAR-CoV-2

Current vaccine efforts to combat SAR-CoV-2 are focused on spike protein, the primary target for neutralizing antibodies. SARS-CoV-2 receptor binding domain (RBD) is immunodominant and accounts for 90% of serum neutralizing activity. In this study, we constructed various versions of SAR-CoV-2 RBD as well as spike protein. Then we conducted several mouse trials to evaluate the immune responses after vaccination of these antigens that are formulated in alum or a Th1 adjuvant DDA/TDB. We would like to identify an optimized RBD-based subunit vaccine for a human clinical trial.

BC CDC Presenters

10/19/2021 6:50:00 PM